Skip to content
Bomb Report – Lifestyle
Author:
Bluejay Diagnostics, Inc.
Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization
August 13, 2026
Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study
July 21, 2026
Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
June 5, 2026
Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
June 2, 2026
Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership
June 2, 2026
Bluejay Diagnostics Provides First Quarter 2026 Corporate Update
May 7, 2026
From Jezebel to Jesus: Cha’liss O Releases a Bold Testimony of Redemption and Spiritual Awakening
April 26, 2026
Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial
April 7, 2026
A Breathtaking Tale of Oaths, Vengeance, and a Kingdom on the Edge
March 17, 2026
Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting
March 12, 2026
1
2
Next Page
→